Biodesix announces new master collaborative research agreement with leading US cancer center

Biodesix, a leading diagnostic solutions company with a focus on lung diseases, has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.

Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK. Bio-Rad will provide its industry-leading digital PCR assay technology in support of this important work.

The collaborators, represented by Dr. Howard Scher (MSK) and Dr. Gary Pestano (Biodesix), shared an update at the 31st International Precision Medicine Tri-Con meeting (PMTC) on March 25, titled: An Industry | Academic Collaboration Framework Focused on Novel Diagnostic Test Development in Oncology.

“The expansion of our previous master sponsored research agreement (MSRA) into a master collaborative research agreement with MSK is a significant milestone for Biodesix and for biomarkers in oncology diagnostics. Biodesix looks forward to co-developing and validating new test concepts under these agreements,” said Scott Hutton, CEO, Biodesix.

“We look forward to working with Biodesix to develop the next generation of highly multiplexed digital PCR assays as part of our expanding oncology offering,” said Simon May, EVP and President of Life Sciences at Bio-Rad Laboratories. “Bio-Rad provides the leading solution for digital PCR, and we are committed to providing oncology researchers and commercial partners with technologies that enable everything from biomarker discovery to clinical trials and patient monitoring of minimal residual disease.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>